Nykode Therapeutics (NYKD) Company presentation summary

Strategic positioning and financial outlook

• Focused on oncology and autoimmune diseases with a proprietary antigen-presenting cell (APC) targeting platform, leveraging AI for drug design and candidate selection.

• Cash runway extends into 2028–2029, supporting key milestones including interim data from the Abili-T trial and progress on the ASIT platform.

• Disciplined cost management and strong financial position enable execution through significant inflection points.

Oncology pipeline and clinical progress

• Abi-suva (VB10.16) is an off-the-shelf DNA-based immunotherapy for HPV16+ cancers, showing strong efficacy and immune response in multiple trials.

• VB10.NEO, an individualized neoantigen therapy, is validated by positive Phase 3 data in the field and demonstrates robust immune activation and correlation with overall survival.

• Abili-T, a randomized Phase 2 trial in 1L head and neck cancer, is ongoing with interim analysis expected in 2027.

Clinical data and market potential

• Abi-suva shows improved overall response rates and survival compared to checkpoint inhibitor monotherapy in HPV16+ head and neck and cervical cancers.

• VB10.NEO demonstrates high rates of vaccine-induced immune responses and durable efficacy across more than 10 tumor types.

• Both assets are supported by simpler and faster manufacturing processes compared to mRNA, enabling competitive cost and turnaround time.